NCT03443843

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

A Double-Blind Placebo-Controlled Crossover Study to Evaluate Objective Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure in an Environmental Exposure Unit

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.

Conditions

• Rhinitis, Allergic

Interventions

Type	Name	Description
DRUG	loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)	Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
DRUG	Placebo tablet	Placebo tablet orally
DRUG	Fluticasone Propionate	Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
DRUG	Placebo spray	Placebo Nasal Spray, 2 sprays per nostril

Timeline

• Start date: 2018-02-21
• Primary completion: 2018-05-11
• Completion: 2018-05-11
• First posted: 2018-02-23
• Last updated: 2019-12-20

Locations

1 site across 1 country: Canada